Vir Biotechnology, Inc. (VIR) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Mon, Feb 23, 2026 | after close | 54 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | after close | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results - Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 - VIR-5500 received Fast Track designation and achieved proof of concept, with pivotal trials to begin next year - Entered collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked T-cell engager development candidates - Ended quarter with approximately $901 million in cash, cash equivalents and investments, excluding $90 million in upfront c" exhibit |
| Q3 FY2026 | "Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027." exhibit |
| Q3 FY2026 | "The Company expects multiple pivotal trials to begin in 2027." exhibit |
| Q3 FY2026 | "Net Loss: Net loss for the third quarter of 2026 was $96.3 million, or $0.57 per share, basic and diluted, compared to a net loss of $163.1 million, or $1.17 per share, basic and diluted for the same period in 2025. 2026 Financial Guidance Based on our current operating plans, the Company continues to expect its cash, cash equivalents and investments to fund operations into the second half of 2028." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment – Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 – Closed global strategic collaboration with Astellas and initiated additional VIR-5500 Phase 1 monotherapy and combination therapy dose-expansion cohorts in patients with metastatic prostate cance" exhibit |
| Q2 FY2026 | "Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027." exhibit |
| Q2 FY2026 | "The Company anticipates initiating pivotal Phase 3 trials in 2027." exhibit |
| Q2 FY2026 | "The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VIR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VIR
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/VIR/"><img src="https://veritasdata.dev/embed/VIR.svg" alt="VIR earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/VIR/)
Script
<script async src="https://veritasdata.dev/embed/VIR.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VIR"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.